Comparative assessment of biologics in treatment of psoriasis: Drug design and clinical effectiveness of ustekinumab

Drug Design, Development and Therapy

Volumn , Issue 5, 2011, Pages 41-49

  Garcia Valladares, Ignacio ^a   Cuchacovich, Raquel ^a   Espinoza, Luis R ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biologics; Psoriasis; Psoriatic arthritis; Tumor necrosis factor inhibitors; Ustekinumab

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; BRIAKINUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; LYMPHOTOXIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ACCESSORY CELL; ANAPHYLAXIS; ARTHRALGIA; BIOLOGICAL THERAPY; CARDIOVASCULAR SYMPTOM; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; DRUG COST; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GENETIC SUSCEPTIBILITY; HUMAN; INFECTION RATE; INJECTION SITE REACTION; LOADING DRUG DOSE; LYMPHOCYTOPENIA; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; REVIEW; SERUM SICKNESS; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; COMPARATIVE STUDY; DRUG ANTAGONISM; IMMUNOLOGY; PSORIATIC ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; DRUG DESIGN; HUMANS; IMMUNOLOGIC FACTORS; PSORIASIS; TH1 CELLS; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952903239     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S10494     Document Type: Review

References (65)

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361: 469-509.
2. Lebwolhl M. Psoriasis. Lancet. 2003;361:1197-1204.
3. Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25:510-518.
4. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866-873.
5. Braun Falco O, Burg G. Inflammatory inf iltrate in psoriasis vulgaris: A cytochemical study. Arch Klin Exp Dermatol. 1970;236: 297-314.
6. Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352: 1899-1912.
7. Warren RB, Griffiths CE. The future of biological therapies. Semin Cutan Med Surg. 2010;29:63-66.
8. Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24 Suppl 2:10-16.
9. Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet. 1997;6:813-820.
10. Bowcock AM, Barker JN. Genetics of psoriasis: The potential impacts on new therapies. J Am Acad Dermatol. 2003;49 Suppl:S51-S56.
11. Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010;42:985-990.
12. Funk J, Langeland T, Schrumpf E, Hanssen LE. Psoriasis induced by interferon-alpha. Br J Dermatol. 1991;125:463-465.
13. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid dendritic cellsinitiate psoriasis through interferon-alpha production. J Exp Med. 2005; 202:135-143.
14. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449:564-569.
15. Madonna S, Scarponi C, Sestito R, et al. The IFN-gamma-dependent suppressor of cytokine signaling 1 promoter activity is positively regulated by IFN regulatory factor-1 and Sp1 but repressed by growth factor independence-1b and Kruppel-like factor-4 and is dysregulated in psoriatic keratinocytes. J Immunol. 2010;185:2467-2481.
16. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950-957.
17. Steiman L. A brief history of TH17, the first major revision in the TH1/ TH2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007;13:139-145.
18. Ma HL, Liang S, Li J, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008;118:597-607.
19. Guilloteau K, Paris I, Pedretti N, et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1α, and TNF-α recapitulates some features of psoriasis. J Immunol. 2010;184: 5263-5270.
20. Garcia-Valladares I, Espinoza LR. Psoriasis pathophysiology. Immunotherapy. 2010;2:444-445.
21. Fitch E, Harper E, Skorcheva I, et al. Pathophysiology of psoriasis: Recent advances on IL-23 and TH17 cytokines. Curr Rheumatol Rep. 2007;9:461-467.
22. Piskin G, Sylva-Steenland RMR, Bos JD, Teunissen MBM. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin. J Immunol. 2006;176:1908-1915.
23. Cuchacovich R, Espinoza LR. Ustekinumab for psoriatic arthritis. Lancet. 2009;373:605-606.
24. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-850.
25. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001; 34:248-255.
26. Papp KA, Carey W. Psoriasis care: New and emerging pharmacologic trends. J Cutan Med Surg. 2010;14:119-129.
27. Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol. 2010;160:810-820.
28. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody. Nat Rev Drug Discov. 2010;9:767-774.
29. Menter A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis. 2009;84(4 Suppl):14-24.
30. Dunn LK, Feldman SR. Alefacept treatment for chronic plaque psoriasis. Skin Therapy Lett. 2010;15:1-3.
31. Menter A, Cather JC, Baker D, et al. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol. 2006;54:61-63.
32. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47:821-833.
33. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719-727.
34. Bissonnette R, Searles G, Landells I, et al. The AWARE study: Methodology and baseline characteristics. J Cutan Med Surg. 2009; 13 Suppl 3:S113-S121.
35. Searles G, Bissonnette R, Landells I, et al. Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study. J Cutan Med Surg. 2009;13 Suppl 3:S131-S138.
36. Perlmutter A, Cather J, Franks B, et al. Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis. J Am Acad Dermatol. 2008;58:116-124.
37. Chaarani J, Lebwohl M. Alefacept: Where it stands today. Expert Opin Drug Metab Toxicol. 2010;6:355-361.
38. Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol. 2010;146:46-54.
39. Prinz J, Braun-Falco O, Meurer M, et al. Chimeric CD4 monoclonal antibody in treatment of generalized pustular psoriasis. Lancet. 1991; 338:320-321.
40. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:1-15.
41. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicenter, double-blind trial. Lancet. 2005;366:1367-1374.
42. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 2000;42: 829-830.
43. Wolbink GJ, Vis M, Lems W, et al. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711-715.
44. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug availability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54:3782-3789.
45. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomized phase III trial. Lancet. 2006;367:29-35.
46. Gottlieb A, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-1632.
47. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy and effect of dose reduction. Br J Dermatol. 2005;152:1304-1312.
48. Romero-Mate A, Garcia-Donoso C, Cordova-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: An updated review. Am J Clin Dermatol. 2007;8:143-155.
49. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106-115.
50. Gordon K. Efficacy and safety of adalimumab treatment in patients with moderate to severe psoriasis: A double-blind, randomized clinical trial.Psoriasis Forum. 2007;13:4-11.
51. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumor necrosis factor naïve patients: A cohort study. Ann Rheum Dis. 2010;69:817-821.
52. van de Kerkhof PC. Novel biologic therapies in development targeting IL-12/IL-23. J Eur Acad Dermatol Venereol. 2010;Suppl 6:5-9.
53. Oppman B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715-725.
54. Butler DM, Malfait AM, Maini RN, et al. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collageninduced arthritis. Eur J Immunol. 1999;29:2205-2212.
55. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody in patients with psoriasis: 76-week results from a randomized, double-blind, placebocontrolled trial (PHOENIX 1). Lancet. 2008;371:1665-1674.
56. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, doubleblind, placebo- controlled trial (PHOENIX 2). Lancet. 2008;371: 1675-1684.
57. Griffiths EM, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118-128.
58. Gospodarevskaya E, Picot J, Cooper K, Loveman E, Takeda A. Ustekinumab for the treatment of moderate to severe psoriasis. Health Technol Assess. 2009;13 Suppl 3:61-66.
59. Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase II trial. J Am Acad Dermatol. 2010;63:457-465.
60. Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: Results from the PHOENIX 1 trial. Br J Dermatol. 2010;162:137-146.
61. Langley R, Papp K, Gottlieb A, et al. Long-term safety and efficacy of ABT-874 for the treatment of moderate to severe psoriasis - interim analysis from an open-label extension study. Available from: http://www.dermatology.ca/conference/2010/2010Abstracts.pdf. Accessed 2010 Dec 2.
62. Reddy M, Torres G, McCormick T, et al. Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters. J Dermatol. 2010;37:413-425.
63. Martin PL, Sachs C, Imai N, et al. Development in the Cynomolgus macaque following administration of ustekinumab, a human anti- IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010;89:351-363.
64. Brodmerkel C, Zhu Y, Jiao Q, et al. Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functions. J Drugs Dermatol. 2010;9:677-683.
65. Ionescu MA, Lipozencic J. Could anti IL12/23 therapy replace anti-TNF biologics? Acta Dermatovenerol Croat. 2009;17:166-169.